Immunotherapy available for tumors identified as dMMR or MSI-H
Patients with unresectable or metastatic solid tumors identified as mismatch repair deficient (dMMR by IHC) or microsatellite instability-high (MSI-H by PCR) who have progressed following other treatments are now eligible for Keytruda®(pembrolizumab) immunotherapy. A recent FDA accelerated approval based on these biomarkers permits the use of Keytruda® immunotherapy in qualified patients, regardless of solid tumor site. For additional details on these biomarker assays, click here.
ASCO Guidelines Update for Stage IV NSCLC Patients